Institutional Investors Control 60% of Altimmune, Inc. (NASDAQ:ALT) and Were Rewarded Last Week After Stock Increased 11%

Simply Wall StSep 13 06:45 ET

JMP Securities Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $24

Moomoo NewsSep 10 17:32 ET · Ratings

Buy Rating Affirmed for Altimmune on Pemvidutide's Positive Trial Data and Strategic Advancements

TipRanksSep 10 16:35 ET · Ratings

Altimmune Spikes After Presenting Data for Obesity Drug

Seeking AlphaSep 10 15:47 ET

Express News | Altimmune Corrects Previous Release; Says Reduction Of Visceral Adipose Tissue (VAT) At Week 48 Adjusted To 28.3% From 25.6%, And Subcutaneous Adipose Tissue Reduction Revised To 19.5% From 20.1%

BenzingaSep 10 13:14 ET

Altimmune Presents Data From Its Phase 2, MRI-Based Body Composition Sub-study Of Pemvidutide In Subjects With Overweight And Obesity

BenzingaSep 10 07:52 ET